Are Vivanza Biosci. latest results good or bad?
Vivanza Biosciences reported impressive revenue growth of 1,745.33% year-on-year in Q2 FY2026, reaching ₹55.36 crores; however, profitability remains a concern with thin margins and negative cash flow, indicating significant operational challenges ahead.
Vivanza Biosciences' latest financial results for Q2 FY2026 present a complex picture characterized by significant revenue growth alongside challenges in profitability and operational efficiency. The company reported net sales of ₹55.36 crores, reflecting a remarkable year-on-year growth of 1,745.33% compared to ₹3.00 crores in Q2 FY2025. This surge in revenue marks the highest quarterly figure in the company's recent history, indicating a strong top-line performance.However, despite this impressive revenue growth, Vivanza's profitability metrics raise concerns. The net profit for the quarter was ₹0.56 crores, which is a substantial increase of 2,700.00% year-on-year, yet the profit margins remain extremely thin. The profit after tax (PAT) margin stood at just 1.01%, suggesting that the company is operating with minimal buffer against potential adverse developments. Additionally, the operating margin declined to 1.08%, a significant reduction from previous periods, indicating a compression in operational efficiency.
The financial results also highlight underlying operational challenges. The company has experienced volatility in revenue, with previous quarters showing drastic fluctuations, which raises questions about the sustainability of this growth. Furthermore, the return on equity (ROE) has been concerning, with the latest figure reported at -16.92%, indicating that shareholder value has been eroded.
In terms of evaluation, Vivanza Biosciences saw an adjustment in its evaluation, reflecting the mixed nature of its financial performance. The company continues to grapple with high financial leverage, as evidenced by a net debt to equity ratio of 2.15 times, and negative cash flow from operations, which turned negative at ₹-2.47 crores in FY2025.
Overall, while Vivanza Biosciences has achieved remarkable revenue growth in its latest quarter, the accompanying operational challenges and thin profit margins suggest that the company faces significant hurdles in establishing a sustainable and profitable business model moving forward.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
